Mobile Health Program to Support HIV Prevention and Reduce Stigma in Young Transgender Women
Tests phone-based programs to support PrEP use in young HIV-negative transgender women.
Plain-language title generated from the registry record
Registry title: Evaluation of mHealth Intervention to Promote HIV Prevention and Overcome Stigma Among Transgender Women (EMPOW.HER)
Key facts
- Where
- Bangkok, ThailandSee the 3 sites
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 29 years old?
Source: NCT07509827, who can take part
Where in Thailand
- Institute of HIV Research and Innovation (IHRI)Bangkok, ThailandTaking people
- Rainbow Sky Association of Thailand (RSAT)Bangkok, ThailandTaking people
- The Service Workers In Group Foundation (SWING)Bangkok, ThailandTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Institute of HIV Research and Innovation Foundation, Thailand
- Trial code
- NCT07509827
- Record updated
- 3 April 2026
- Original description
This study aims to develop and evaluate a multi-component mHealth intervention (mHC and FRESH) to reduce HIV-related and intersectional stigma and improve PrEP use among HIV-negative young transgender women (TGW) in Thailand.Read full original descriptionShow less
Evaluation of mHealth Intervention to Promote HIV Prevention and Overcome Stigma Among Transgender Women (EMPOW.HER)
This study aims to develop and evaluate a multi-component mHealth intervention (mHC and FRESH) to reduce HIV-related and intersectional stigma and improve PrEP use among HIV-negative young transgender women (TGW) in Thailand.
Inclusion: Age 18-29 years; Male sex at birth; Self-identify as transgender woman/female spectrum; HIV-negative (laboratory confirmed); Recent condomless sex; Able to understand Thai; Not on PrEP or poorly adherent (≤3 pills/week).
Exclusion: Serious cognitive or psychiatric condition affecting consent; Active suicidal ideation or major mental illness; Enrolled in another HIV intervention study; Medical contraindications to PrEP.